Literature DB >> 30033617

A practical Bayesian adaptive design incorporating data from historical controls.

Matthew A Psioda1, Mat Soukup2, Joseph G Ibrahim1.   

Abstract

In this paper, we develop the fixed-borrowing adaptive design, a Bayesian adaptive design which facilitates information borrowing from a historical trial using subject-level control data while assuring a reasonable upper bound on the maximum type I error rate and lower bound on the minimum power. First, one constructs an informative power prior from the historical data to be used for design and analysis of the new trial. At an interim analysis opportunity, one evaluates the degree of prior-data conflict. If there is too much conflict between the new trial data and the historical control data, the prior information is discarded and the study proceeds to the final analysis opportunity at which time a noninformative prior is used for analysis. Otherwise, the trial is stopped early and the informative power prior is used for analysis. Simulation studies are used to calibrate the early stopping rule. The proposed design methodology seamlessly accommodates covariates in the statistical model, which the authors argue is necessary to justify borrowing information from historical controls. Implementation of the proposed methodology is straightforward for many common data models, including linear regression models, generalized linear regression models, and proportional hazards models. We demonstrate the methodology to design a cardiovascular outcomes trial for a hypothetical new therapy for treatment of type 2 diabetes mellitus and borrow information from the SAVOR trial, one of the earliest cardiovascular outcomes trials designed to assess cardiovascular risk in antidiabetic therapies.
© 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Bayesian design; adaptive design; clinical trial design; historical control; power prior

Mesh:

Substances:

Year:  2018        PMID: 30033617      PMCID: PMC6327964          DOI: 10.1002/sim.7897

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  13 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

3.  Robust meta-analytic-predictive priors in clinical trials with historical control information.

Authors:  Heinz Schmidli; Sandro Gsteiger; Satrajit Roychoudhury; Anthony O'Hagan; David Spiegelhalter; Beat Neuenschwander
Journal:  Biometrics       Date:  2014-10-29       Impact factor: 2.571

4.  EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.

Authors:  William B White; George L Bakris; Richard M Bergenstal; Christopher P Cannon; William C Cushman; Penny Fleck; Simon Heller; Cyrus Mehta; Steven E Nissen; Alfonso Perez; Craig Wilson; Faiez Zannad
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

5.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

7.  The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; Ph Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Deborah L Price; Roland Chen; Jacob Udell; Itamar Raz
Journal:  Am Heart J       Date:  2011-11       Impact factor: 4.749

8.  Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program.

Authors:  Ming-Hui Chen; Joseph G Ibrahim; H Amy Xia; Thomas Liu; Violeta Hennessey
Journal:  Stat Med       Date:  2013-12-16       Impact factor: 2.373

9.  Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

Authors:  Jennifer B Green; M Angelyn Bethel; Sanjoy K Paul; Arne Ring; Keith D Kaufman; Deborah R Shapiro; Robert M Califf; Rury R Holman
Journal:  Am Heart J       Date:  2013-10-23       Impact factor: 4.749

10.  The power prior: theory and applications.

Authors:  Joseph G Ibrahim; Ming-Hui Chen; Yeongjin Gwon; Fang Chen
Journal:  Stat Med       Date:  2015-09-07       Impact factor: 2.373

View more
  3 in total

1.  BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data.

Authors:  Barry S Eggleston; Joseph G Ibrahim; Becky McNeil; Diane Catellier
Journal:  J Stat Softw       Date:  2021-11-30       Impact factor: 6.440

2.  A new path for CF clinical trials through the use of historical controls.

Authors:  Amalia S Magaret; Mark Warden; Noah Simon; Sonya Heltshe; George Z Retsch-Bogart; Bonnie W Ramsey; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2021-12-05       Impact factor: 5.482

3.  An adaptive power prior for sequential clinical trials - Application to bridging studies.

Authors:  Adrien Ollier; Satoshi Morita; Moreno Ursino; Sarah Zohar
Journal:  Stat Methods Med Res       Date:  2019-11-15       Impact factor: 3.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.